

J GREGORY CAIRNCROSS

Curriculum Vitae

September 2008

J GREGORY CAIRNCROSS, MD

PLACE OF BIRTH London, Ontario, CANADA

CITIZENSHIP Canadian

MEDICAL LICENCE NO (CPSA) 013206

BUSINESS ADDRESS

Department of Clinical Neurosciences
Foothills Medical Centre, Room 1195
1403-29th Street N.W.
Calgary, Alberta,
T2N 2T9
Telephone 403-944-1260;
Fax 403-270-7878;
e-mail jgcairn@ucalgary.ca
e-mail gregory.cairncross@calgaryhealthregion.ca

HOME ADDRESS

410 11th St. N.W.
Calgary, AB, T2N 1X4
CANADA

EDUCATION

St Michael's Separate School, London, Ontario, 1956-1963
Denis Morris High School, St. Catharines, Ontario, 1963-1966
St Jerome's High School, Kitchener, Ontario, 1966-1968
University of Western Ontario, 1968-1970 (mathematics program)
University of Western Ontario, 1970-1974, M.D. (cum laude)

POSTGRADUATE TRAINING

Intern (Medicine), Toronto General Hospital, 1974-1975.
Assistant Resident (Medicine), Toronto General Hospital, 1975-1976
Assistant Resident (Neurology), New York Hospital, 1976-1978
Chief Resident (Neurology), New York Hospital, 1978-1979
Research Fellow (Immunobiology), Sloan Kettering Institute for Cancer Research, 1979-1981
Clinical Fellow (Neuro-Oncology), Memorial Hospital for Cancer & Allied Diseases, 1979-1981
Professional Leadership Program, Faculty of Medicine, University of Western Ontario, 1997

BOARD CERTIFICATION

FRCP(C), Medicine, 1979
FRCP(C), Neurology, 1979
ABPN (American Board of Psychiatry & Neurology), 1982

ADMINISTRATIVE ROLES**Leadership Positions:**

Chief, Department of Clinical Neurological Sciences, Victoria Hospital, London, Ontario, 1993-1996
Head, Division of Neurology, Clinical Neurological Sciences, University of Western Ontario, 1996-1998
Chief Executive Officer, London Regional Cancer Centre, London, Ontario, 1998-2002
Vice President, Cancer Care Ontario - Southwest Region, 1998-2002
Chair, Department of Oncology, University of Western Ontario, 1998-2002
Head, Department of Clinical Neurosciences, University of Calgary, 2002-present
Regional Clinical Department Head, Clinical Neurosciences, Calgary Health Region, 2002-present

Administrative Activities (Internal):

Appointments, Promotion and Tenure Committee, Department of Clinical Neurological Sciences, University of Western Ontario (UWO), 1982-1984; 1990-2000
Postgraduate Training Committee, Department of Oncology, University of Western Ontario, 1984-1990
Research Advisory Committee, Clinical Neurological Sciences, Victoria Hospital, 1985-1988
Selection Committee, Director, London Regional Cancer Centre, 1986
Selection Committee, Head, Medical Oncology, London Regional Cancer Centre, 1987
Selection Committee, Chief of Clinical Neurological Sciences, Victoria Hospital, 1987
Member, Dean's Advisory Committee on Oncology, 1987
Postgraduate Training Committee, Department of Clinical Neurological Sciences, 1988-1990
Chair, CNS Multidisciplinary Team, London Regional Cancer Centre, 1988 - 1998
Appointments, Promotion and Tenure Committee, Department of Oncology, 1989 - 2002
Member, Selection Committee, Chief, Oncology, Victoria Hospital, 1990
Member, Selection Committee, Chief, Surgical Oncology, London Regional Cancer Centre, 1992
Head, Division of Neurology, Victoria Hospital, 1993-1995
Executive Committee, Clinical Neurological Sciences, University of Western Ontario, 1993 - 2002
Member, Medical Advisory Committee, Victoria Hospital, 1993-1996
Coordinator, Ontario Cancer Genetics Network, London Regional Cancer Centre, 1994-1995
Committee, Chair of Clinical Neurological Sciences, University of Western Ontario, 1995
Committee, Drake Professorship, Clinical Neurological Sciences, University of Western Ontario, 1998
Acting Director, Clinical Research Unit, London Regional Cancer Centre, 1998-2000
Chief, Department of Oncology, London Health Science Centre, 1999-2002
Selection Committee, Chair of Clinical Neurological Sciences, University of Western Ontario, 2000
Selection Committee, Chair, Department of Pathology, University of Western Ontario, 2000
Chair, Executive Team, Department of Clinical Neurosciences, University of Calgary, 2002-present
Member, Department Heads Committee, University of Calgary, 2002-present
Member, Regional Clinical Department Heads Committee, 2002-present
Member, Medical Advisory Board, Calgary Health Region, 2002-present
Member, Priorities & Planning Committee, Faculty of Medicine, University of Calgary, 2003-present
Co-chair, Steering Committee, Hotchkiss Brain Institute, 2002-2004
Member, Strategic Advisory Board, Hotchkiss Brain Institute, 2004-present
Co-chair, Department Heads Committee, Faculty of Medicine, University of Calgary, 2005-present
Member, Medical Advisory Board Executive Committee, Calgary Health Region, 2005-present
Director, Clark H Smith Brain Tumor Centre, University of Calgary, 2007-present

Administrative Activities (External):

Co-Chair, Neuro-Oncology Scientific Session, American Academy of Neurology, 1986
Chair, Neuro-Oncology Course, Canadian Congress of Neurological Sciences, 1986
Chair, Organizing Committee, 3rd Canadian Neuro-Oncology Meeting, 1988

Co-Chair, National Cancer Institute of Canada Clinical Trials Group, Phase II Study of "Intensive PCV-3" chemotherapy for recurrent anaplastic oligodendroglioma, 1989
Reviewer (neuro-oncology papers), American Academy of Neurology, 1990
Chair, Neuro-Oncology Scientific Session, American Academy of Neurology, 1990
Chair, Neuro-Oncology Course, Canadian Congress of Neurological Sciences, 1991
Co-Chair, Neuro-Oncology Scientific Session, American Academy of Neurology, 1992
Co-Chair, Neuro-Oncology Scientific Session, American Academy of Neurology, 1994
Chair, Brain Tumor Educational Session, American Society of Clinical Oncology, 1994
Chair, RTOG Intergroup Phase III, Oligodendroglioma Trial, 1994
Conference Chair, Breast Cancer: Genetics to Aesthetics, 1994
Chair, Neuro-Oncology Section, American Academy of Neurology, 1994-1996
Member, Advisory Committee, 11th International Conference on Brain Tumor Research, 1995
Chair, Canadian Brain Tumor Working Group, 1995-1999
Chair, Brain Committee, National Cancer Institute of Canada's Clinical Trials Group, 1996-2008
Member, National Brain Tumor Foundation Scientific Advisory Committee, 1997-present
Membership Committee, American Society of Clinical Oncology, 1998-2003
Board Member (ex officio), Canadian Brain Tumor Consortium, 1999-present
Chair, Provincial CNS Disease Site Committee, Cancer Care Ontario, 1991-2000
Chair, Preuss Award Committee, American Academy of Neurology, 1999-2001
Member, Brain Tumor Progress Review Group, NCI/NINDS (US), 2000
Member, Canadian Cancer Society's Cancer Information Service Network of Expert Reviewers, 2000
Member, Selection Committee, Farber Award, 2000- 2002
Member, Preuss Award Committee, American Academy of Neurology, 2001-2005
Chair, CNS Subcommittee, ASCO Program Committee, 2002
External Scientific Advisory Board, University of Alabama, Brain Tumor Center, 2003-2007
External Scientific Advisory Board, Pediatric Brain Tumor Consortium, 2002-2005
External Scientific Advisory Board, MD Anderson Cancer Center, Brain Tumor SPORE, 2005-present
Chair, Scientific Program Committee, Annual Research Conference of the Alberta Cancer Board, 2006
External Data Safety Monitoring Board, Adult Brain Tumor Consortium (NCI/CTEP), 2008-present

ACADEMIC APPOINTMENTS

Instructor (Neurology), Cornell University Medical College, 1979-1981
Research Associate, Sloan Kettering Institute for Cancer Research, 1981-1982
Assistant Professor (Neurology), Cornell University Medical College, 1981-1982
Assistant Professor (Oncology/CNS), University of Western Ontario, 1982-1987
Associate Professor (Oncology/CNS), University of Western Ontario, 1987-1991
Professor (Oncology), University of Western Ontario, 1991-2004
Member, Graduate Program in Neuroscience, University of Western Ontario, 1995-2004
Professor (Clinical Neurosciences), University of Calgary, 2002-present
Member, Cancer Biology Research Group, University of Calgary, 2002-2004
Member, Hotchkiss Brain Institute, University of Calgary, 2005-present
Associate Member, Southern Alberta Cancer Research Institute, University of Calgary, 2005-present

Honorary Appointments:

Lecturer (Microbiology/Immunology), University of Western Ontario, 1984 - 2002.
Professor (Medicine), University of Western Ontario, 1991 - 2002.

HOSPITAL APPOINTMENTS

Attending Neurologist, Memorial Hospital for Cancer & Allied Diseases, 1981-1982
Attending Neurologist, New York Hospital, 1981-1982
Attending Neurologist, London Regional Cancer Centre, 1982-2002
Attending Neurologist, London Health Science Centre, 1982-2002
Consultant Neurologist, St. Joseph's Health Centre, 1984-2002

Current:

Attending Neurologist, Foothills Medical Centre, 2002-present
Consultant Neurologist, Tom Baker Cancer Centre, 2002-present

SCHOLARLY ACTIVITIES**Awards and Honors:**

Ontario Scholar, 1968
London Life Actuarial Scholarship, 1968
Helen Atfield White Scholarship, 1970
MRC Summer Research Scholarship, 1971
Alpha Omega Alpha, 1972
CIBA Prize in Medicine, 1972
MRC Summer Research Scholarship, 1972
Kingswood Scholarship, 1974
MRC Centennial Fellowship, 1979-81
American Cancer Society Fellowship, 1981-82
Teacher-Investigator Award, NINCDS, 1981-82
Fellow, American Academy of Neurology, 1985
Elected Member, American Neurological Association, 1992
"Best Doctors in America", 1992, 1994
Farber Award, American Association of Neurological Surgeons, 1996
American Brain Tumor Association Research Excellence Award, 1998
Dean's Award of Excellence for Research, University of Western Ontario, 1999
Voynick Award for Brain Tumor Research, Yale University School of Medicine, 2000
Award of Merit, European Association for Neuro-oncology, 2002
Alberta Cancer Foundation Chair in Brain Tumor Research, 2002
Arête Award for Research Excellence, University of Calgary, 2008

Grant Support:

National Cancer Institute of Canada (\$80,000), 1983-1985
"Astrocytoma subsets defined by differentiation antigens"

National Cancer Institute of Canada (\$76,000), 1985-1987
"Astrocytoma subsets defined by differentiation antigens"

Amyotrophic Lateral Sclerosis Society of Canada (\$30,000), 1985-1986
"A cell growth factor from the CNS"
(Co-Investigators, M.P. Rathbone and R.L. Carlone)

Cancer Research Society (\$60,000), 1985-1987
"A growth factor from brain: Its role in normal brain and brain tumors"
(Co-Investigators, M.P. Rathbone and R.L. Carlone)

Ministry of Health Clinical Research Equipment Award (\$15,000), 1987
"Experimental Studies on Metastatic Potential of Brain Tumor Cells"
(Co-Investigator, A. Chambers)

National Cancer Institute of Canada (\$25,000), 1987-1988
"Differentiation Induction in Human Glioblastoma Cell Lines"

Ontario Mental Health Foundation (\$20,000), 1987-1989
"Cognitive Function in Longterm Survivors with Slow and Fast-Growing Primary Brain Tumors"
(Co-Investigator, Y. Archibald)

National Institutes of Health (\$40,000), 1987-1989
"Malignant Human Gliomas and Medulloblastomas"
(Principal Investigator, D. Bigner)

Victoria Hospital Research Development Fund (\$10,000), 1989-1990
"Characterization of IN/157: A Putative Human Oligodendroglioma Cell Line"

National Institutes of Health (\$25,000), 1989-1990
"Malignant Human Gliomas and Medulloblastomas"
(Principal Investigator, D. Bigner)

The Upjohn Company (\$102,000), 1990-1991
"Steroid-induced MR Scan Changes in Patients With Malignant Glioma"

Victoria Hospital Research Development Fund (\$15,000), 1990-1991
"Familial Glioma"

Cancer Research Society (\$100,000), 1991-1993
"Familial Astrocytoma"

Victoria Hospital Research Development Fund (\$7,293), 1991-1992
"MGMT Activity in Glial Cell Lineages"

Victoria Hospital Research Development Fund (\$13,888), 1993-1994
"Genes in Brain Regulated by p53"

LRCC Endowment Fund (\$50,900), 1993-1995
"Drug Resistance in Glial Cells"

National Institutes of Health (\$280,000), 1994-1998
"CNS Cancer Consortium"
(Principal Investigator, D.R. Macdonald)

National Cancer Institute of Canada (\$165,000), 1994-1997
"Brain Tumor Tissue Bank"
(Principal Investigator, D.A. Ramsay)

LRCC Endowment Fund (\$20,000), 1995-1996

"p53-dependent genes in the developing brain"

Victoria Hospital Research Development Fund (\$14,000), 1995-1996
"Effect of p53 on resistance of astrocytes to BCNU"

Victoria Hospital Corporation (\$50,000), 1995-1997
"Brain Tumor Research"

LHSC - Internal Research Fund (\$14,000), 1996-1997
"p53-mediated BCNU resistance in astrocytes"

Medical Oncology Research Fund (\$10,000), 1996-1997
"p53, MGMT and drug resistance in astrocytes"

Brain Tumor Foundation of Canada (\$10,000), 1997-1998
"p53, MGMT and drug resistance in astrocytes"

LRCC Endowment Fund (\$21,300), 1997-1998
"p53 and oligodendrocyte precursor growth and survival"

Medical Oncology Research Fund (\$10,000), 1997-1998
"Molecular analysis of chemosensitive astrocytic gliomas"

LHSC - Internal Research Fund (\$14,000), 1998-1999
"Mechanism of p53-mediated BCNU resistance in astrocytes"

Cancer Care Ontario (\$25,000), 1998
"Molecular workshop - oligodendroglioma"

LRCC Endowment Fund (\$22,000), 1998-1999
"Molecular determinants of drug response in glial tumors"

Medical Oncology Research Fund (\$14,100), 1998-1999
"p53 and drug resistance in human astrocytomas"

LRCC Endowment Fund (\$40,000), 1999-2000
"Molecular determinants of drug response in glial tumors"

Canadian Institutes of Health Research (\$289,134), 2000-2003
"Molecular determinants of drug response in glial tumors"

Lawson Health Research Institute (\$12,000), 2001-2002
"Molecular determinants of radiosensitivity in glial tumors"

Alberta Cancer Board (\$34,995), 2003-2005
"Imaging correlates of molecular signatures in low grade glioma"

Cancer Research Society (\$120,000), 2004-2006
"The effect of p53 status on the chemosensitivity of glioma cells"

Alberta Heritage Foundation for Medical Research (\$400,000), 2005-2007
“Integrative Brain Tumor Research Centre”

Hotchkiss Brain Institute (\$370,000), 2006-2009
“A passport to discovery for the brain tumor patient”

Terry Fox Research Institute (\$750,000), 2008-2010
“Personalized treatment for patients with glioblastoma”

Alberta Cancer Research Institute (\$1,025,500), 2008-2011
“New Targets and Novel Treatments for Brain Tumor”

Patents:

U.S. Patent 4,642,291 issued February 10, 1987

U.S. Patent 4,806,628 issued March 17, 1989

Editorial Board Memberships:

Canadian Journal of Neurological Sciences, 1998-2008

Neuro-Oncology, 1998-present

Journal of Neuro-Oncology, 1999-present

Journal of Clinical Oncology 2000-2003

Grant Review Panels:

National Cancer Institute of Canada, 1985

Medical Research Council of Canada, Cancer Committee, 1988-1990

National Institutes of Health, Special Review Committee, 1992

National Institutes of Health, Special Review Committee, 1995

National Institutes of Health, CNS Cancer Consortium Review Team (chair), 2003

Ad Hoc Grant Reviews (2000-2006):

Medical Research Council of Canada

National Cancer Institute of Canada

Dutch Cancer Society

National Institutes of Health

Albert Cancer Board

Medical Research Council (UK)

Genesis Oncology Trust (NZ)

Ad Hoc Manuscript Reviews (2000-2006):

Annals of Neurology

Neurology

Journal of American Medical Association

British Journal of Cancer

Journal of Neurological Sciences

Archives of Neurology

Cancer

Neurosurgery

Brain

Clinical Cancer Research

Canadian Journal of Neurological Sciences

Journal of Clinical Oncology

Biochemical Pharmacology

Cancer Research

Lancet

Annals of Oncology

International Journal of Cancer

New England Journal of Medicine

Professional Societies:

American Academy of Neurology, 1976-present
Ontario Medical Association, 1982-2002
London Academy of Medicine, 1982-2002
American Association for Neurological Investigation, 1982-1988
Canadian Association of Medical Oncologists, 1988-1998
American Neurological Association, 1992-present
Joint Section on Tumors of AANS and CNS, 1992-1998 (elected Honorary Member, 2002)
Society for Neuro-Oncology, 1995-present
American Society of Clinical Oncology, 1996-present
Alberta Medical Association, 2002-present
Canadian Medical Association, 2002-present

Board Memberships:

Society for Neuro-Oncology, 1995-1999
Lawson Health Research Institute, London, Ontario, 2000-2002

TEACHING ACTIVITIES**Undergraduate Students:**

Clinical Methods Course, Cornell University Medical College, 1980-1982
Neuroscience Course, University of Western Ontario, 1982-1998
Clinical Methods Course, University of Western Ontario, 1982-1998
Supervisor, Ravindra Conway, Computer Science Co-op student, University of Waterloo
(January - April 1988 and September - December 1988)
Supervisor, Yasemin Ikizler, Medical Student, University of Toronto, June - September 1990
(Ms. Ikizler won the G. Milton Shy Essay Contest, American Academy of Neurology, 1991)
Clinical Clerkship Program, London Regional Cancer Centre, 1999-2002
Clinical Skills Teaching (Neurosciences), University of Calgary, 2005-2007

Postgraduate Students:

Neurology resident supervisor: Cornell University Medical College, 1981-1982; University of Western Ontario, 1982-2002; University of Calgary, 2002-present
Neuro-Oncology elective supervisor: Rob Semmler, 1988; Randal Florell, 1991; Ramesh Sajpaul, 1992; Chris Watling, 1993; Neil Brown, 1995; Peter Pahapill, 1996.
Lecturer, Biology of Human Cancer, Pathology 500b, Introductory Course, 1993, 1994

Graduate Students:

Donald van Meyel PhD
Department of Microbiology/Immunology, University of Western Ontario, PhD (1996)
"P53-dependent tumorigenesis and gene expression in brain"
Assistant Professor, McGill University

Catherine Nutt PhD
Department of Pathology, University of Western Ontario, PhD (1997)
"Mechanisms of drug resistance in glial cells"
Assistant Professor, Harvard Medical School

Magdalena Zlatescu MSc

Neuroscience Program, University of Western Ontario, MSc (1998)
“Molecular determinants of chemotherapeutic response in gliomas”
Associate Radiologist, Calgary Health Region and University of Calgary

John Charalambopoulos MSc
Department of Microbiology/Immunology, University of Western Ontario, MSc (2002)
“Influence of p53 on radioresponse in U87MG glioma cells”
Resident, Internal Medicine, Georgetown University, Washington, DC

Guo Wei Xu PhD
Neuroscience Program, University of Western Ontario, PhD (2004)
“p53 and chemosensitivity in astrocytic glioma cells”
Research Associate, University Health Network, Toronto, ON

Michael Blough MSc
Southern Alberta Cancer Research Institute, University of Calgary, PhD candidate (2004-present)

Morgan Westgate BSc
Southern Alberta Cancer Research Institute, University of Calgary, MSc candidate (2007-present)

Postdoctoral Fellows:

Ramin Suishansian, PhD, Experimental Oncology, London Regional Cancer Centre, 1997
Guo Wei Xu, PhD (China), Experimental Oncology, London Regional Cancer Centre, 1998-2000

Neuro-Oncology Fellowship Supervisor:

Dr. Michel Rathbone, 1984-1985 (Professor, McMaster University)
Dr. Michael Winger, 1987-1988 (Private Practice, Windsor, Ontario)
Dr. Sarah Kirby, 1992-1993 (Clinical Associate Professor, Dalhousie University)
Dr. Joanne Bacchus, 1993-1994 (Private Practice, Toronto, Ontario)
Dr. David Fortin, 1997-1998 (Associate Professor, University of Sherbrooke)
Dr Sajeel Chowdhary, 2003-2004 (Clinical Assistant Professor, University of South Florida)
Dr Gloria Roldan, 2005-2008
Dr Paula de Robles, 2007-present

Other Teaching:

Meet the Professor, ASCO, 1997
Meet the Professor, ASCO, 2002
ASCO Speakers Bureau Program, 1999-present

PUBLICATIONS

Peer Reviewed Articles:

1. Cairncross JG, Chernik NL, Kim J-H, Posner JB: Sterilization of cerebral metastases by radiation therapy. **Neurology** 29: 1195-1202, 1979.

2. Cairncross JG, Salmon J, Kim J-H, Posner JB: Acute parotitis and hyperamylasemia following whole brain radiation therapy. **Ann Neurol** 7: 385-387, 1980.
3. Cairncross JG, Kim J-H, Posner JB: Radiation therapy for brain metastases. **Ann Neurol** 7: 529-541, 1980.
4. Cairncross JG, Mattes MJ, Beresford HR, Albino AP, Houghton AN, Lloyd KO, Old LJ: Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. **Proc Natl Acad Sci USA** 79: 5641-5645, 1982.
5. Houghton AN, Eisenger M, Albino AP, Cairncross JG, Old LJ: Surface antigens of melanomas and melanocytes: markers for melanocyte differentiation and melanoma subsets. **J Exp Med** 156: 1755-1766, 1982.
6. Wang E, Cairncross JG, Yung W-KA, Garber EA, Liem RKH: An intermediate filament associated protein, p50, recognized by monoclonal antibodies. **J Cell Biol** 97: 1507-1514, 1983.
7. Mattes MJ, Cairncross JG, Old LJ, Lloyd KO: Monoclonal antibodies to three widely distributed human cell surface antigens. **Hybridoma** 2: 253-264, 1983.
8. Wang E, Cairncross JG, Liem RKH: Identification of glial filament protein and vimentin (decamin) in the same intermediate filament system in human glioma cells. **Proc Natl Acad Sci USA** 81: 2102-2106, 1984.
9. Zochodne DW, Cairncross JG, Arce FP, Macdonald JCF, Blume WT, Girvin JP, Kaufmann JCE: Astrocytoma following scalp radiotherapy in infancy. **Can J Neurol Sci** 11: 475-478, 1984.
10. Cairncross JG, Pexman JHW, Rathbone MP: Postsurgical contrast enhancement mimicking residual brain tumor. **Can J Neurol Sci** 12: 75, 1985.
11. Clinicopathological Conference: Complications of chemotherapy. **Can J Neurol Sci** 12: 149-153, 1985.
12. Cairncross JG, Pexman JHW, Rathbone MP, Del Maestro RF: Postoperative contrast enhancement in brain tumor patients. **Ann Neurol** 17: 570-572, 1985.
13. Cairncross JG, Denhardt GH: Cell density dependent glial filament (GF) expression in a human astrocytoma clonal cell line. **Ann NY Acad Sci** 455: 771-773, 1985.
14. Filmus J, Pollak MN, Cairncross JG, Buick RN: Amplified, over-expressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. **Biochem Biophys Res Comm** 131: 207-215, 1985.
15. Schold SC, Mahaley MS, Vick NA, Friedman HS, Burger PC, DeLong ER, Albright RE, Bullard DE, Khandekar JC, Cairncross JG, Macdonald DR, Falleta JM: Phase II Diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. **J Clin Oncol** 5: 464-471, 1987.
16. Cairncross JG: The biology of astrocytoma: lessons learned from chronic myelogenous leukemia - hypothesis. **J Neuro-Oncol** 5: 99-104, 1987.

17. Shafran B, Roke ME, Barr RM, Cairncross JG: Contrast enhancing PML lesions: a clinicopathological correlation. **Can J Neurol Sci** 14: 600-602, 1987.
18. Cairncross JG, Macdonald DR, Pexman JHW, Ives FJ: Steroid-induced CT scan changes in patients with recurrent malignant glioma. **Neurology** 38: 724-726, 1988.
19. Cairncross JG, Macdonald DR: Successful chemotherapy for malignant oligodendroglioma. **Ann Neurol** 23: 360-364, 1988.
20. Walker RW, Cairncross JG, Posner JB: Cerebral herniation complicating cisplatin therapy. **J Neuro-Oncol** 6: 61-65, 1988.
21. Johnston EA, Hammond AJ, Cairncross JG: Bilateral hypoglossal palsies - a late complication of curative radiotherapy. **Can J Neurol Sci** 16: 198-199, 1989.
22. Jennings MT, Jennings VDL, Asadourian LLH, Rosenblum M, Albino AP, Cairncross JG, Old LJ: Five novel cell surface antigens of CNS neoplasms. **J Neurol Sci** 89: 63-78, 1989.
23. Winger MJ, Macdonald DR, Schold SC, Cairncross JG: Selection bias in clinical trials of anaplastic glioma. **Ann Neurol** 26: 531-534, 1989.
24. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic glioma in adults - prognostic importance of extent of resection and prior low grade glioma. **J Neurosurg** 71: 487-493, 1989.
25. Macdonald DR, O'Brien RA, Gilbert JJ, Cairncross JG: Metastatic anaplastic oligodendroglioma. **Neurology** 39: 1593-1596, 1989.
26. Cairncross JG, Eisenhauer EA, Macdonald DR, Rathbone RP, Moore MJ, Sawka CA, MacCormick RE, Kerr IG: Phase II study of trimetrexate in patients with recurrent malignant glioma: a National Cancer Institute of Canada Clinical Trials Group study. **Can J Neurol Sci** 17: 21-23, 1990.
27. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. **Ann Neurol** 27: 573-574, 1990.
28. Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of malignant glioma. **J Clin Oncol** 8: 1277-1280, 1990.
29. Chambers AF, Wilson SM, Tuck AB, Denhardt GH, Cairncross JG: Comparison of metastatic properties of a variety of mouse, rat and human cells in assays in nude mice and chick embryos. **In Vivo** 4: 215-220, 1990.
30. Chambers AF, Denhardt GH, Wilson S, Cairncross JG: Malignant properties of P635 glioma are independent of glial fibrillary acid protein expression. **J Neuro-Oncol** 11: 43-48, 1991.
31. Cairncross JG, Macdonald DR: Chemotherapy for oligodendroglioma - progress report. **Arch Neurol** 48: 225-227, 1991.
32. Mikkelsen T, Cairncross JG, Cavenee WK. Genetics of the malignant progression of astrocytoma. **J Cell Biochem** 46: 3-8, 1991.

33. Glantz MJ, Burger PC, Herndon JE, Friedman AH, Cairncross JG, Vick NA, Schold SC JR: Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. **Neurology** 41: 1741-1744, 1991.
34. Florell RC, Macdonald DR, Irish WD, Bernstein M, Leibel SA, Gutin PH, Cairncross JG: Selection bias, survival and brachytherapy for glioma. **J Neurosurg** 76: 179-183, 1992.
35. Chandarana P, Young GB, Macdonald DR, Cairncross JG, Archibald YM: Unusual neuropsychiatric symptoms as a manifestation of a frontotemporal tumor. **Neuropsychiat Neuropsychol Behav Neurol** 5: 53-55, 1992.
36. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma - a chemosensitive tumor. **Neurosurgery** 31: 78-82, 1992.
37. Gaspar LE, Fisher B, Macdonald DR, Leber DV, Halperin EC, Schold SC, Cairncross JG: Supratentorial anaplastic glioma: patterns of recurrence and implications for external beam local treatment. **Int J Radiat Oncol Biol Phys** 24: 55-57, 1992.
38. Iking Y, Van Meyel DJ, Ramsay DA, Abdallah GL, Allaster RM, Macdonald DR, Cavenee WK, Cairncross JG: Gliomas in families. **Can J Neurol Sci** 19: 492-497, 1992.
39. Schold SC, Herndon JE, Burger PC, Halperin EC, Vick NA, Cairncross JG, Macdonald DR, Dropcho EJ, Morawetz R, Bigner DD, Mahaley MS: A randomized comparison of Diaziquone and Carmustine in the treatment of adults with anaplastic glioma. **J Clin Oncol** 11: 77-83, 1993.
40. Gaspar LE, Fisher BT, Macdonald DR, Leber DV, Halperin EC, Schold SC, Cairncross JG: Malignant glioma - timing of response to radiation therapy. **Int J Radiat Oncol Biol Phys** 25: 877-879, 1993.
41. Stewart DJ, Eisenhauer E, Macdonald D, Cairncross JG, Langleben A: Phase II study of Tiazofurin in gliomas in adults: a National Cancer Institute of Canada study. **J Neuro-Oncol** 15: 175-179, 1993.
42. Gaspar LE, Mackenzie IRA, Gilbert JJ, Kaufmann JCE, Fisher BJ, Macdonald DR, Cairncross JG: Primary cerebral fibrosarcomas: clinicopathologic study and review of the literature. **Cancer** 72: 3277-3281, 1993.
43. Van Meyel DJ, Ramsay DA, Chambers AF, Macdonald DR, Cairncross JG: Absence of hereditary mutations in exons 5-9 of the p53 gene and exon 24 of the neurofibromin gene in families with glioma. **Ann Neurol** 35: 120-122, 1994.
44. Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HWK, Pexman JHW, Fisher BJ, Gaspar LE, Cairncross JG: Cognitive functioning in long term survivors of high-grade glioma. **J Neurosurg** 80: 247-253, 1994.
45. Van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG: p53 mutation, expression and DNA ploidy in evolving gliomas: evidence for two pathways of progression. **J Natl Cancer Inst** 86: 1011-1017, 1994.

46. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG: A prospective study of short course radiotherapy in poor prognosis glioma. **Int J Radiat Oncol Biol Phys** 29: 835-839, 1994.
47. Watling CJ, Lee DH, Macdonald DR, Cairncross JG: Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. **J Clin Oncol** 12: 1886-1889, 1994.
48. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Wainman N, Eisenhauer E: Chemotherapy for anaplastic oligodendroglioma. **J Clin Oncol** 12: 2013-2021, 1994. **(Editorial commentary by Howard Fine)**
49. Rogers LR, Weinstein MA, Estes ML, Cairncross JG, Strachan T: Diffuse bilateral cerebral astrocytomas with atypical neuroimaging studies. **J Neurosurg** 81: 817-821, 1994.
50. Watling CJ, Van Meyel DJ, Ramsay DA, Macdonald DR, Cairncross JG: Loss of heterozygosity analysis of chromosomes 9, 10 and 17 in gliomas in families. **Can J Neurol Sci** 22: 17-21, 1995.
51. Nutt CL, Costello JF, Bambrick LL, Yarosh DB, Swinnen LE, Chambers AF, Cairncross JG: O⁶-Methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage. **Can J Neurol Sci** 22: 111-115, 1995.
52. Kirby S, Brothers M, Irish W, Florell R, Macdonald D, Schold C, Cairncross G: Evaluating glioma therapies - modeling treatments and predicting outcomes. **J Natl Cancer Inst** 87: 1884-1888, 1995.
53. Halperin EC, Herndon J, Schold SC Jr, Brown M, Vick N, Cairncross JG, Macdonald D, Gaspar L, Dropcho E, Rosenfeld R, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Burger P, Gentel G, Friedman A: A phase III randomized prospective trial of external beam radiotherapy, Mitomycin C, BCNU and 6-Mercaptopurine for the treatment of adults with anaplastic glioma of the brain. **Int J Radiat Oncol Biol Phys** 34: 793-802, 1996.
54. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. **Ann Oncol** 7: 205-207, 1996.
55. Kirby SA, Macdonald DR, Fisher BF, Gaspar LE, Cairncross JG: Pre-radiation chemotherapy for anaplastic glioma. **Can J Neurol Sci** 23: 123-127, 1996.
56. Nutt CL, Chambers AF, Cairncross JG: Wild-type p53 renders mouse astrocytes resistant to 1,3-Bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53-dependent cell cycle arrest. **Cancer Res** 56: 2748-2751, 1996.
57. Peterson K, Paleologos N, Forsyth P, Macdonald D, Cairncross G: Salvage chemotherapy for oligodendroglioma. **J Neurosurg** 85: 597-601, 1996.
58. Forsyth P, Cairncross G, Macdonald D, Stewart D, Goodyear M, Fulton D, Wainman N, Eisenhauer E: Phase II trial of docetaxel in patients with recurrent malignant glioma. **Invest New Drugs** 14: 203-206, 1996.
59. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, Macdonald D, Cairncross G: Supratentorial low grade glioma in adults: An analysis of prognostic factors and timing of radiation. **J Clin Oncol** 15: 1294-1301, 1997. **(Editorial commentary by Edward Shaw)**

60. Forsyth PAJ, Petrov E, Mahallati H, Brasher P, Cairncross JG, MacRae ME, Hagen NA, Sevick RJ: Prospective study of post-operative MR imaging in patients with malignant glioma. **J Clin Oncol** 15: 2076-2081, 1997.
61. Gao L, Liu L, van Meyel D, Cairncross G, Forsyth P, Kimmel D, Jenkins R, Lassam N, Hogg D: Lack of germline mutations of CDK4, p16^{INK4A} and p15^{INK4B} in families with glioma. **Clin Cancer Res** 3: 977-982, 1997.
62. Perry JR, DeAngelis LM, Schold SC Jr, Burger PC, Brown MT, Brem HS, Curran WJ, Scott CB, Prados MD, Kaplan R, Cairncross JG: Challenges in the design and conduct of phase III brain tumor therapy trials. **Neurology** 49: 912-917, 1997.
63. Irish WD, Macdonald DR, Cairncross JG: Measuring bias in uncontrolled brain tumor trials - to randomize or not to randomize? **Can J Neurol Sci** 24: 307-312, 1997. (**Editorial commentary by William Shapiro**)
64. Bauman GS, Fisher BJ, Cairncross JG, Macdonald DR: Bihemispheric malignant glioma: One size does not fit all. **J Neuro-oncol** 28: 83-89, 1998.
65. Patel A, van Meyel D, Malhopatra G, Cairncross G, Feuerstein B: Gliomas in families: chromosomal analysis by comparative genomic hybridization . **Cancer Genet & Cytogenet** 100: 77-83, 1998.
66. Fisher B, Bauman GS, Leighton C, Stitt L, Cairncross JG, Macdonald DR: Pediatric low-grade gliomas: volume response to radiation. **J Neurosurg** 88: 969-974, 1998.
67. Fisher B, Bauman G, Leighton C, Macdonald D, Cairncross J, Stitt L: Pediatric low-grade gliomas: volume response to radiation. **Neurosurgical Focus** 4:1-10, 1998.
68. Scott JN, Rewcastle NB, Brasher PMA, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P: Long-term glioblastoma multiforme survivors: a population-based study. **Can J Neurol Sci** 25: 197-201, 1998.
69. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. **J Natl Cancer Inst** 90: 1473-1479, 1998.
70. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy? **Ann Neurol** 44: 691-695, 1998.
71. van Meyel DJ, Sanchez-Sweatman O, Ramsay DA, Chambers AF, Cairncross JG: Genetic background influences timing, morphology and dissemination of lymphomas in p53-deficient mice. **Int J Onc** 13: 917-922, 1998.
72. Bauman GS, Pahapill PA, Fisher BJ, Macdonald DR, Leighton CC, Cairncross JG: Low-grade glioma: Measuring radiographic response to radiotherapy. **Can J Neurol Sci** 26: 18-22, 1999.

73. Taylor MD, Perry J, Zlatescu MC, Stemmer-Rachaminor AO, Ang LC, Ino Y, Schwartz M, Becker L, Louis DN, Cairncross JG: hPMS2 exon 5 mutation and malignant glioma: Case report and molecular genetic study. **J Neurosurg** 90: 946-950, 1999.
74. Scott JN, Rewcastle NB, Brasher PMA, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P. Which GBM patient will become a long-term survivor? A population-based study. **Ann Neurol** 46: 183-188, 1999.
75. Pohl U, Cairncross JG, Louis DN: Homozygous deletions of the *CDKN2C/p18^{INK4C}* gene on chromosome 1p in anaplastic oligodendrogliomas. **Brain Pathology** 9: 639-643, 1999.
76. Nutt CL, Loktionova NA, Pegg AE, Chambers AF, Cairncross JG: O⁶-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. **Carcinogenesis** 20:2361-2365, 1999.
77. Paleologos N, Macdonald D, Vick N, Cairncross G: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. **Neurology** 53: 1141-1143, 1999.
78. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, Macdonald D, Stitt L, Cairncross G: Pretreatment factors predict overall survival for patients with low grade glioma: a recursive partitioning analysis. **Int J Rad Oncol Biol Phys** 45: 923-929, 1999.
79. Cairncross JG, Swinnen L, Bayer R, Rosenfeld S, Vaughan W, Paleologos N, Kaminer L, Forsyth P, Stewart D, Macdonald D, Ramsay D, A Smith: Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. **Neuro-Oncology** 2: 114-119, 2000.
80. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. **Neurology** 54: 1886-1893, 2000.
81. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, Ramsay DA, von Deimling A, Louis DN, Cairncross JG: Long survivals and therapeutic responses in histologically disparate high-grade gliomas with chromosome 1p loss. **J Neurosurg** 92: 983-990, 2000. **(Editorial commentary by Webster Cavenee)**
82. Nutt CL, Noble M, Chambers AF, Cairncross JG: Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. **Cancer Res** 60:4812-4818, 2000.
83. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. **Int J Rad Oncol Biol Phys** 43: 825-830, 2000.
84. Louis DN, Posner JB, Jacobs T, Kaplan R. Report of the Brain Tumor Progress Review Group. http://ospncinihgov/Prg_assess/PRG/BTPRG/2000. (JG Cairncross was a core member of the NCIC / NINDS (US) Progress Review Group).
85. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. **Clin Cancer Res** 7:839-845, 2001.

86. Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG: Inactivation of p53 sensitizes U87MG glioma cells to 1,3-Bis (2-chloroethyl)-1-nitrosourea. **Cancer Res** 61: 4155-4159, 2001.
87. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. **Am J Pathol** 159: 359-367, 2001.
88. Fortin D, Macdonald DR, Stitt L, Cairncross JG: PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. **Can J Neurol Sci** 28: 215-223, 2001. (**Editorial commentary by Peter Forsyth and Douglas Stewart**)
89. Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. **Am J Pathol** 159: 779-786, 2001.
90. Zlatescu MC, TehraniYazdi AR, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. **Cancer Res** 61: 6713-5, 2001.
91. Jenkins RB, Curran W, Scott CB, Cairncross JG. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a National Cooperative Cancer Treatment Group. **Am J Clin Onc** 24:506-508, 2001.
92. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low grade "oligodendroglioma". **J Neuropathol Exp Neurol** 61: 58-63, 2002.
93. Li Y, Betensky RA, Louis DN, Cairncross JG. The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and power. **Biometrics** 58: 232-236, 2002.
94. Louis DN, Pomeroy SL, Cairncross JG. Focus on central nervous system neoplasia. **Cancer Cell** 1: 125-128, 2002.
95. Sasaki H, Betensky RA, Cairncross JG, Louis DN: *DMBT1* polymorphisms: relationship to malignant glioma tumorigenesis. **Cancer Res** 62: 1790-1796, 2002.
96. Betensky R, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. **J Clin Oncol** 20: 2495-2499, 2002.
97. Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerkviet N, Forton D, Macdonald DR, Cairncross JG, Bauman GS, Stitt L. Ki-67: A prognostic factor for low-grade glioma? **Int J Rad Oncol Biol Phys** 52: 996-1001, 2002.
98. Watling C, Cairncross JG: Acetazolamide for symptomatic plateau waves in brain tumor patients. **J Neurosurg** 97:224-226, 2002.
99. Laperriere N, Zuraw L, Cairncross G and the Cancer Care Ontario Practice Guidelines Initiative Neuro-oncology Disease Site Group: Radiotherapy for newly diagnosed malignant glioma in

- adults: A systematic review. **Radiotherapy & Oncology** 64:259-273, 2002.
100. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, Laughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR and Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. **Cancer Res** 63: 1602-1607, 2003.
 101. Betensky, RA, Louis, DN, Cairncross, JG. Analysis of a molecular genetic neuro-oncology study with partially biased selection. **Biostatistics** 4: 167-178, 2003.
 102. Forsyth PA, Weaver S, Fulton D, Brasher PMA, Sutherland G, Stewart D, Hagen NA, Barnes P, Cairncross JG, De Angelis LM. Prophylactic anticonvulsants in patients with brain tumor. **Can J Neurol Sci** 30: 106-112, 2003.
 103. van den Bent M, Chinot O, Cairncross JG. Temozolomide: Recent developments in the molecular characterization and treatment of oligodendroglial tumors. **Neuro-Oncology** 5: 128-138, 2003.
 104. Belanger K, Macdonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with anaplastic oligodendroglioma and anaplastic mixed oligoastrocytoma. **Investigational New Drugs** 21: 473-480, 2003.
 105. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith A, Macdonald DR, Weaver S, Ramsey DA, Nimer S, DeAngelis LM, Cairncross JG. High dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. **J Neuro-Oncol** 65: 127-134, 2003.
 106. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. An abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. **J Clin Oncol** 22: 1583-1588, 2004. **(Editorial commentary by Edward Shaw)**
 107. Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG. Imaging correlates of genetic signatures in oligodendrogliomas. **Clin Cancer Res** 10: 4303-4306, 2004.
 108. Chang S, Seiferfeld W, Curran W, Share R, Atkins J, Choucair A, Kresl J, Thoron L, Cairncross G, Gilbert M, Bahary J-P, Dolinskas C, Louis D, Bushunow P, Buckner J, Barger G, Mehta M: Phase I study pilot arms of radiation therapy and BCNU with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): Implications for studies testing initial treatments for brain tumors. **Int J Rad Oncol Biol Phys** 59: 1122-1126, 2004.
 109. Xu GW, Mymryk J, Cairncross JG. Inactivation of p53 sensitizes D54MG and A172 astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. **J Neuro-Oncol** 74: 141-149, 2005.
 110. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO on behalf of the European Organisation for Research and treatment of Cancer (EORTC) Brain Tumor and Radiotherapy

- Groups and National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. **N Engl J Med** 352: 987-996, 2005.
111. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason WP, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross G, Janzer R, Stupp R. MGMT gene silencing and response to temozolomide in glioblastoma. **New Engl J Med** 352: 997-1003, 2005.
112. Xu GW, Mymryk J, Cairncross JG. Pharmaceutical mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. **Int J Cancer** 116: 187-192, 2005.
113. Webster M, Panasci L, Cairncross G, Gertler S, Perry J, Wainman N, Eisenhauer E. Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea. A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group. **Invest New Drugs** 23: 591-596, 2005.
114. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith A, Macdonald DR, Weaver S, Ramsey DA, Nimer S, DeAngelis LM, Cairncross JG. High dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long term follow-up. **Neuro-Oncology** 6: 183-188, 2006.
115. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta, M, Curran W on behalf of the Radiation Therapy Oncology Group (RTOG), Northcentral Cancer Treatment Group (NCCTG), Southwest Oncology Group (SWOG), National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and Eastern Cooperative Oncology Group (ECOG). A randomized clinical trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma. **J Clin Oncol** 24: 2707-2714, 2006. (**Editorial commentary by Mark Gilbert and Frederick Lang**)
116. Mirimanoff RO, Gorlia T, Mason W, van den Bent M, Kortmann R, Fischer B, Reni M, Brandes A, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC.CE3 Phase III randomized trial. **J Clin Oncol** 24: 2563-2569, 2006.
117. Tang P, Roldan G, Brasher P, Fulton D, Roa W, Murtha A, Easaw J, Cairncross G, Forsyth P. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. **J Neuro-Oncol** 78: 311-316, 2006.
118. Blough M, Zlatescu M, Cairncross G. MGMT regulation by p53 in astrocytic cells. **Cancer Res** 67: 580-584, 2007.
119. Betensky RA, Louis DN, Cairncross JG. Tests of association under misclassification: Application to histological sampling in oncology. **Statistics in Medicine** 26: 4808-4816, 2007.
120. Abrey LE, Louis DN, Paleologos NA, Lassman AB, Raizer JJ, Mason W, Finlay J, Weaver S, Forsyth PA, Macdonald DR, Lieberman F, Rosenfeld S, DeAngelis LM, Cairncross JG for the Oligodendroglioma Study Group. A survey of practice patterns for anaplastic oligodendroglioma. **Neuro-Oncology** 9: 314-318, 2007.

121. Perry J, Laperriere N, Zuraw L, Chambers A, Cairncross G, on behalf of the Neuro-oncology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. Chemotherapy following surgery and radiotherapy for adults with malignant glioma: a systematic review. **Can J Neurol Sci** 34: 402-410, 2007.
122. Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A. The prognostic value of health-related quality of life data in predicting survival in glioblastoma cancer patients: results from an international randomized phase III EORTC Brain Cancer Group Study. **Br J Cancer** 97: 302-307, 2007.
123. Fisher B, Leighton C, Macdonald D, Stitt L, Bauman G, Cairncross G. The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. **J Neuro-Oncol** 82: 165-170, 2007.
124. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Cairncross G, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma multiforme: a prognostic factor analysis of EORTC/NCIC trial 26981-22981/CE.3. **Lancet Oncol** 9: 29-38, 2008.
125. Roldán G, Scott JN, George D, Easaw J, Yan E, Parney I, Cairncross G, Forsyth P. Leptomeningeal disease from oligodendroglioma: a clinical and molecular analysis. **Can J Neurol Sci** 35: 204-209, 2008.
126. Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Vallee-Matthews M, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. **Molecular Therapy** 16: 627-632, 2008.
127. Brown R, Zlatescu M, Sijben A, Forsyth P, Parney I, Sevick R, Demetrick D, Schiff D, Cairncross G, Mitchell R. Detecting genetic signatures in oligodendroglioma non-invasively using MR. **Clin Cancer Res** 14: 2357-2362, 2008.
128. Roldán G, Li H, Brasher P, Vecil G, Senger D, Rewcastle BV, Cairncross G, Forsyth P, Hamilton M. A population-based study of medulloblastoma: survival, prognostic factors and Collins law violators. **Can J Neurol Sci** 35: 211-215, 2008.
129. Sijben AE, McIntyre JB, Roldán GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. **J Neuro-Oncol** 89: 97-103, 2008.
130. Hegi M, Murat A, Migliavacca E, Gorlia T, Lambiv W, Shay T, Hamou M-F, Diserens A-C, Luca R, Wick W, Kouwenhoven M, Hainfellner J, Heppner F, Dietrich P-Y, Zimmer Y, Macdonald D, Guha A, Merlo A, Cairncross G, de Tribolet N, Janzer R-C, Domany E, Delorenzi M, Stupp R. Self-renewal signature" and high EGFR expression associated with resistance to chemo-radiotherapy in glioblastoma. **J Clin Oncol** 26: 3015-3024, 2008.
131. Mohile NM, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly

- diagnosed anaplastic oligodendroglioma: An interim analysis. **J Neuro-Oncol** 89: 187-194, 2008.
132. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Radiation Therapy Oncology Group trial 9402. *Am J Surg Pathol* 18: 360-369, 2008.
 133. de Robles P, McIntyre J, Kalra S, Roldan G, Cairncross G, Forsyth P, Magliocco A, Hamilton M, Easaw J. Methylation status of the *MGMT* gene promoter in meningiomas. *Canc Genet Cytogenet* (in press).
 134. Delaney L, Chambers C, Roldan G, de Robles P, Cairncross G, Forsyth P, Easaw J. A feasibility study to access the integration of a pharmacist into the neuro-oncology clinic. *J Oncol Pharm Prac* (in press)
 135. Colman H, Zhang L, Sulman E, McDonald J, Shooshtari N, River A, Hothorn T, Popoff S, Wei C, Nutt C, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, McDonald JM, Mehta MP, Chakravarti A, Pelloski C, Bhat K, Yung A, Feuerstein BG, Yeh R-F, Jenkins RB, Aldape K. A multigene classifier of outcome in glioblastoma (submitted)
 136. Kelly JJP, Chojnacki A, Lun X, Sun B, Stechisin O, Senger DL, Forsyth PF, Auer RN, Dunn L, Cairncross JG, Parney IF, Weiss S. Mitogen-Independent Human Brain Tumor Stem Cells. (submitted).
 137. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Radiation Therapy Oncology Group trial 9402. *Am J Surg Pathol* 18: 360-369, 2008.
 138. Bauman G, Fisher B, Watling C, Leighton C, Cairncross G, Macdonald D. Adult supratentorial low-grade glioma: long term experience at a single institution (submitted).
 139. Lwu S, Hamilton MG, Forsyth PA, Cairncross JG, Parney IF. Practice patterns for peri-operative anti-epileptic drug use in newly diagnosed patients with malignant glioma (submitted).
 140. Delaney L, Chambers C, Roldan G, de Robles P, Cairncross JG, Forsyth PA, Easaw J. A Feasibility study to assess the integration of a pharmacist into the neuro-oncology clinic (submitted).

Other Peer-Reviewed Publications:

1. Cairncross G, Perry J and the Neurooncology Disease Site Group (2004). Use of temozolomide in the treatment of newly diagnosed or recurrent malignant glioma: an evidence based summary. <http://www.cancercare.on.ca/pdf/pebc9-5esf.pdf>
2. Brown RA, Zlatescu MC, Cairncross JG, Mitchell JR (2006). Texture analysis for non-invasive identification of brain tumor genotype from MRI. *Visualization, Imaging, and Image Processing* 480-116: 459-464 http://www.actapress.com/content_of_proceeding.aspx?proceedingID=317
3. Bjarnason TA, Drabycz S, Adler DH, Cairncross G, Mitchell JR (2007). Applying the s-transform to magnetic resonance imaging texture analysis. *Fields Institute Communications Series. Pseudo-*

Differential Operators: PDEs and Time-Frequency Analysis. Eds. Rodino L, Schulze BW, Wong MW, pp 311-322.

Editorials:

1. Cairncross JG, Laperriere NJ. Low grade glioma: to treat or not to treat? **Arch Neurol** 46: 1238-1239, 1989.
2. Cairncross JG, Laperriere NJ. Low-grade gliomas: to treat or not to treat? (reply) **Arch Neurol** 47: 1139, 1990.
3. Gaspar LE, Cairncross JG. Hyperthermia and brachytherapy for glioma: will cooler heads prevail? **Int J Rad Oncol Biol Phys** 24: 803-804, 1992.
4. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas: which ones and why? **J Clin Oncol** 15: 3423-3426, 1997.
5. DeAngelis LM, Cairncross JG. Biology and treatment of malignant glioma. **Oncology** 12: 240-246, 1998.
6. Mintz AP, Cairncross JG. Treatment of a single brain metastasis: the role of radiation following surgical resection. **J Amer Med Assoc** 280: 1527-1529, 1998.
7. Cairncross JG. Understanding low-grade glioma - a decade of progress. **Neurology** 54: 1402-1403, 2000.
8. DeAngelis LM, Cairncross JG. A better way to find tumor in the CSF? **Neurology** 58: 339-340, 2002.
9. Perry JR and Cairncross JG. Glioma therapies: how to tell which work? **J Clin Oncol** 21: 3547-3549, 2003.
10. Cairncross JG. Treatment of brain metastasis. **J Supp Oncol** 2: 411-412, 2004
11. Cairncross JG. Imaging molecular signatures in oligodendroglioma. **Clin Cancer Res** 10: 7109-7111, 2004.

Letters to the Editor:

1. Cairncross JG: Scopolamine psychosis revisited. **Ann Neurol** 13: 582, 1983.
2. Cairncross JG, Pexman JHW, Rathbone MP, Del Maestro RF: Postoperative contrast enhancement in brain tumor patients. **Ann Neurol** 19: 611-612, 1986.
3. Cairncross JG, Macdonald DR: Treatment of oligodendrogliomas. **J Neurosurg** 70: 155, 1989.
4. Macdonald DR, Cairncross JG: Surgery for brain metastasis. **N Engl J Med** 323: 132, 1990.
5. Cairncross JG, Macdonald DR: Oligodendroglioma: a new chemosensitive tumor. **J Clin Oncol** 8: 2090-2091, 1990.

6. Gaspar LE, Schold SC JR, Cairncross JG: Surgery for anaplastic glioma. **J Neurosurg** 74: 1027-1028, 1991.
7. Cairncross JG, Macdonald DR: Interferon beta for recurrent malignant glioma. **J Clin Oncol** 10: 672, 1992.
8. Cairncross JG, Eisenhauer EA: Response and control - lessons from oligodendroglioma. **J Clin Oncol** 13: 2475-2476, 1995.
9. Leighton C, Cairncross JG: Low grade glioma - the Europeans are winning. **J Clin Oncol** 15: 2761, 1997.
10. Bauman GS, Cairncross JG: Radiation and chemotherapy improve outcome in oligodendroglioma. **Int J Rad Onc Biol Phys** 37: 779, 1997.
11. Cairncross JG: Cognition in survivors of high-grade glioma. **J Clin Oncol** 16: 2130-3211, 1998.
12. Louis DN, Ino Y, Cairncross JG: High-Grade Gliomas with Chromosome *1p* Loss. **J Neurosurg** 92: 1080-1081, 2000.
13. Cairncross JG: Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes. **J Neuro-Oncol** 46: 157, 2000.

Books:

Practical Management of Low Grade Gliomas. Eds J Rock, M Rosenblum, E Shaw, G Cairncross. Lippincott-Raven, Philadelphia, 2000.

Neurological Therapeutics - Principles and Practice. Ed JN Noseworthy Martin Dunitz, London, UK (Neuro-Oncology Section Editor for first and second Editions)

Book Reviews:

Cairncross JG: Cancer in the nervous system. **Arch Neurol** 53: 1219, 1996.

Cairncross JG: The Gliomas. **N Engl J Med** 341(20): 1554, 1999.

Publications Abstracted for Medical Yearbooks:

"Year Book of Cancer 1983" Cairncross JG, Mattes MJ, Beresford HR, Albino AP, Houghton AN, Lloyd KO, Old LJ: Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. **Proc Natl Acad Sci USA** 79: 5641-5645, 1982.

"Year Book of Cancer 1984" Houghton AN, Eisenger M, Albino AP, Cairncross JG, Old LJ: Surface antigens of melanomas and melanocytes: markers for melanocyte differentiation and melanoma subsets. **J Exp Med** 156: 1755-1766, 1982.

"Year Book of Neurology and Neurosurgery 1989" Cairncross JG, Macdonald DR: Successful chemotherapy for malignant oligodendroglioma. **Ann Neurol** 23: 360-364, 1988.

"Year Book of Neurology and Neurosurgery 1991" Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic glioma in adults - prognostic importance of extent of resection and prior low grade glioma. **J Neurosurg** 71: 487-493, 1989.

"Year Book of Oncology 1993" Florell RC, Macdonald DR, Irish WD, Bernstein M, Leibel SA, Gutin PH, Cairncross JG: Selection bias, survival & brachytherapy for glioma. **J Neurosurg** 76: 179-183, 1992.

"Year Book of Pathology 2001" Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. **Clin Cancer Res** 7:839-845, 2001.

Publications Reprinted in *Classic Papers from the Journal of Clinical Oncology*:

Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of malignant glioma. **J Clin Oncol** 8: 1277-1280, 1990.

Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Wainman N, Eisenhauer E: Chemotherapy for anaplastic oligodendroglioma. **J Clin Oncol** 12: 2013-2021, 1994.

Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, Macdonald D, Cairncross G: Supratentorial low grade glioma in adults: An analysis of prognostic factors and timing of radiation. **J Clin Oncol** 15: 1294-1301, 1997.

Chapters/Review Articles:

1. Cairncross JG, Posner JB: Neurological complications of malignant lymphoma. In: **Handbook of Clinical Neurology**, Vol 39, Eds PJ Vinken, GW Bruyn. Elsevier/North-Holland, Amsterdam, 1979, pp 27-62.
2. Cairncross JG, Posner JB: Neurological complications of systemic cancer. In: **Oncologic Emergencies**, Chap 4. Eds JW Yarbro & RS Bornstein. Grune & Stratton, New York, 1981, pp 73-96.
3. Cairncross JG, Posner JB: Management of brain metastases. In: **Oncology of the Nervous System**, Chap 13. Eds MD Walker. Martinus Nijhoff, Boston, 1983, pp 341-377.
4. Cairncross JG: Neurological emergencies in cancer patients. In: **13th International Cancer Congress**, Part D: Research and Treatment. Eds EA Mirand, WB Hutchinson, E Mihich. Alan R Liss, New York, 1983, pp 319-328.
5. Cairncross JG, Posner JB: Brain tumors in the elderly. In: **Clinical Neurology of Aging**. Ed ML Albert. Oxford University Press, New York, 1984, pp 445-457.
6. Schold SC, Cairncross JG, Bullard DE: Chemotherapy of primary central nervous system neoplasms. In: **Neurosurgery**. Ed RH Wilkins, SS Rengachary. McGraw-Hill, New York, 1985, pp 1143-1152.

7. Cairncross JG: Management of carcinomatous meningitis and acute cord compression. In: **Current Therapy in Neurologic Disease**. Ed RT Johnson. BC Decker. Philadelphia, 1985, pp 216-220.
8. Cairncross JG: Monoclonal antibodies: Applications to the biology, diagnosis and treatment of brain tumors. In: **American Academy of Neurology-Course #205**, 1985.
9. Cairncross JG: Brain Metastasis. In: **American Academy of Neurology - Course #101**, 1986.
10. Cairncross JG: Astrocytoma. In: **Astrocytes, Vol. 3**. Eds S Fedoroff, A Vernadakis. Academic Press, Orlando, 1986, pp 337-356.
11. Cairncross JG: Carcinomatous meningitis. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1989, pp 419-421.
12. Cairncross JG: CNS emergencies. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1989 pp, 437-441.
13. Cairncross JG: Lumbar puncture. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1989, pp 31-32.
14. Cairncross JG: Paraneoplastic syndromes. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1989, pp 610-613.
15. Cairncross JG: CNS staging. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1989, pp 51-53.
16. Cairncross JG: Tumors of the nervous system. In: **Textbook of Internal Medicine**. Ed WN Kelley. Lippincott, Philadelphia, 1989, pp 2418-2423.
17. Cairncross JG: Biology and treatment of well-differentiated gliomas. In: **American Academy of Neurology - Course #440**, 1989.
18. Zochodne DW, Cairncross JG: Metastasis to the central nervous system. In: **Cancer Growth and Progression - Metastasis/Dissemination**. Ed H Kaiser. Kluwer Academic Publishers, Dordrecht, the Netherlands, 1989, pp 32-39.
19. Cairncross JG: Biology of Astrocytoma. **The Cancer Journal** 3: 170-175, 1990.
20. Cairncross JG: Intermediate and low-grade gliomas: progress and controversies. In: **American Academy of Neurology - Course #330**, 1991.
21. Cairncross JG: Guest Editorial: Back Pain and Cancer. In: *Oncore* 1990, pp 1-2.
22. Cairncross JG: Cranial neuropathy. In: **Neurological Complications of Cancer Treatment**. Ed DA Rottenberg. Butterworths, Boston, 1991, pp 63-68.
23. Cairncross JG: Tumors of the nervous system. In: **Textbook of Internal Medicine, 2nd Edition**. Ed WN Kelley. Lippincott, Philadelphia, 1991, pp 2183-2189.

24. Cairncross JG, Macdonald DR: Carcinomatous meningitis. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1991, pp 305-307.
25. Cairncross JG, Macdonald DR: CNS emergencies. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1991, pp 317-319.
26. Cairncross JG, Macdonald DR: Lumbar puncture. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1991, pp 22-23.
27. Cairncross JG, Macdonald DR: Paraneoplastic syndromes. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1991, pp 436-438.
28. Cairncross JG, Macdonald DR: CNS staging. In: **Manual of Oncologic Therapeutics**. Ed RE Wittes. Lippincott, Philadelphia, 1991, pp 37-39.
29. Cairncross JG: Neuro-oncology: is there a role for chemotherapy in the treatment of malignant gliomas? In: **American Academy of Neurology - Course #144**, 1992.
30. Cairncross JG: Aggressive oligodendroglioma: a chemosensitive tumor. In: **Molecular Neuro-oncology and its Impact on the Clinical Management of Brain Tumors**. Ed OD Wiestler, U Schlegel, J Schramm. Springer-Verlag, Berlin, 1994, pp 127-134.
31. Cairncross JG: Low grade glioma - the case for delayed surgery. In: **Clin Neurosurg**. Ed C Loftus. Williams & Wilkins, Baltimore, 1995, vol 42, pp 391-398.
32. Peterson K, Cairncross JG: Oligodendroglioma. In: **Neurologic Clinics**. Ed PY Wen, PMcL Black. W.B. Saunders, Philadelphia, 1995, vol 13, pp 861-873.
33. Bacchus JN, Cairncross JG: Conservative treatment of low grade glioma. In: **Controversies in Neurosurgery**. Ed O Al-Mefty, TC Oritano, HL Harkey. Thieme Medical Publishers Inc, New York, 1995, pp 55-63.
34. Forsyth PAJ, Cairncross JG: Treatment of malignant glioma in adults. In: **Current Opinion in Neurology**. Ed PC Phillips. Current Science, London, 1995, vol 8, pp 414-418.
35. Peterson K, Cairncross JG: Oligodendroglioma. **Cancer Investigation** 14(3): 243-251, 1996.
36. Schabet M, Cairncross JG: Brain metastases from systemic solid tumors. In: **Neurological Disorders: Course and Treatment** Eds T Brandt, LR Caplan, J Dichgans, HC Diener, C Kennard, Academic Press, San Diego, 1996, pp 605-616.
37. Forsyth PAJ, Cairncross JG: Chemotherapy for malignant glioma. In: **Clinical Neurology - Cerebral Gliomas**. Ed W-KA Yung. Bailliere Tindall, London, 1996, vol 5, pp 371-393.
38. Schold SC, Cairncross JG, Sajpaul R: Chemotherapy of primary central nervous system neoplasms. In: **Neurosurgery**. Ed RH Wilkins, SS Rengachary. McGraw-Hill, New York, 1996, pp 1957-1966.
39. DeAngelis LM, Cairncross JG: Tumors of the nervous system. In: **Textbook of Internal Medicine, 3rd Edition**. Ed WN Kelley. Lippincott, Philadelphia, 1997, pp 2331-2339.

40. Cairncross JG: Oligodendroglioma. In: **Cancer of the Nervous System**. Eds P McL Black and JS Loeffler. Blackwell Scientific, Cambridge 1997, pp 549-557.
41. Perry JR, Cairncross JG: Oligodendroglioma. In: **Handbook of Clinical Neurology**. Eds PJ Vinken, GW Bruyn. Elsevier/North Holland, Amsterdam, 1997, pp 123-136.
42. Pech IV, Peterson K, Cairncross JG: Chemotherapy for brain tumor. **Oncology** 12: 537-543, 1998.
43. Paleologos N, Cairncross G: Treatment of oligodendroglioma: An update. **Neuro-Oncology** 1(1): 61-68, 1999.
44. Bampoe J, Bauman G, Cairncross G, Bernstein M: Adult low grade gliomas: natural history, prognostic factors and timing of treatment. In: **Low Grade Glioma**. Ed J Rock, E Shaw, G Cairncross, M Rosenblum. Lippincott-Raven, Philadelphia, pp 135-148, 1999.
45. Perry JR, Louis DN, Cairncross JG: Treatment of oligodendroglioma. **Arch Neurol** 56:434-438, 1999.
46. Fortin D, Cairncross JG, Hammond RR: Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment. **Neurosurgery** 45(6):1279-91, 1999.
47. DeAngelis LM, Cairncross JG: Approach to the patient with tumors of the central nervous system. In: **Textbook of Internal Medicine, 4th Edition**. Ed WN Kelley. Lippincott, Philadelphia, pp 2846-2854, 2000.
48. Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck S, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA: Importance of dose-intensity in neuro-oncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. **Neuro-Oncology** 3(1): 46-54, 2001.
49. Bauman GS, Cairncross JG: Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. **Seminars in Radiation Oncology** 11(2):170-180, 2001.
50. Cairncross JG: A perspective on neuro-oncology. In: **Neurological Therapeutics**. Ed. JN Noseworthy. Martin Dunitz, London, UK, 2002, pp 659-660.
51. Senger D, Cairncross JG, Forsyth PAJ: Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? **The Cancer Journal** 9: 214-221, 2003.
52. Nutt CL, Stemmer-Rachamimov AO, Cairncross JG, Louis DN: Molecular pathology of nervous system tumors. In: **Brain Tumors**. Ed. F Ali-Osman. Humana Press, Totowa, NJ, 2004, pp 33-53.
53. Senger D, Cairncross G, Forsyth P: Long-Term Survivors of glioblastoma: statistical aberration or important unrecognised molecular subtype. In: **Glioblastoma Multiforme**. Ed. JM Markert, VT DeVita and S Hellman. Jones & Bartlett, Boston, MA, 2004, pp 190-205.
54. Mason W, Cairncross JG: Drug insight: temozolomide as a treatment for malignant glioma: impact of a recent trial. **Nature Clinical Practice Neurology** 1: 88-95, 2005.

55. Cairncross JG: A perspective on neuro-oncology. In: **Neurological Therapeutics**. Ed. JN Noseworthy. Martin Dunitz, London, UK, 2006, pp 749-750.
56. Stupp R, Cairncross JG: Medical treatment of malignant glioma. In: **Principles and Practice of Stereotactic Radiosurgery** Ed. L Chin and R Regine. Springer, New York, NY, 2006, pp 223-231.
57. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG: Changing paradigms: an update on the multidisciplinary management of malignant glioma. **The Oncologist** 11: 165-180, 2006.
58. Mason W, Cairncross JG. The expanding impact of molecular biology on the diagnosis and treatment of glioma. **Neurology** 71: 365-373, 2008.
59. Roldan G, de Robles P, Cairncross JG. Searching for a new treatment for anaplastic oligodendroglioma. In: **New Treatment for Brain Cancer (International Oncology Updates Series)**. Ed. C Balañá (in press).
60. Cairncross JG, Jenkins RA. Gliomas with 1p/19q Co-deletion (a.k.a. Oligodendroglioma). **Cancer Journal** (in press).

Abstracts (available on request)

INVITED LECTURES

1. "Cell surface characteristics of cultured human malignant astrocytomas defined by monoclonal antibodies", Research Seminar, Mayo Clinic, Rochester, Minnesota, September 1982.
2. "Neurological complications of cancer", Princess Margaret Hospital, Toronto, Ontario, November 1982.
3. "Cell surface antigens of cultured human malignant gliomas", Princess Margaret Hospital, Toronto, Ontario, November 1982.
4. "Surface antigens of cultured human malignant astrocytomas: markers for astrocytoma subsets and astrocyte differentiation", Neurology Rounds, M. D. Anderson Hospital and Tumor Institute, Houston, Texas, October 1983.
5. "Surface antigens of cultured human malignant astrocytomas: markers for astrocytoma subsets and astrocyte differentiation", Research Seminar, Institute for Cell Biology, University of Essen, Essen, West Germany, October 1984.
6. "Surface antigens of cultured human malignant astrocytomas: markers for astrocytoma subsets and astrocyte differentiation", Neuro-pathology Research Seminar, Queens University, Kingston, Ontario, November 1984.

7. "Surface antigens of cultured human malignant astrocytomas: markers for astrocytoma subsets and astrocyte differentiation", Biological Sciences Research Seminar, Brock University, St. Catharines, Ontario, November 1984.
8. "Diagnosis and treatment of malignant glioma", Guest speaker, Atlantic Neuroscience Meeting, Halifax, Nova Scotia, April 1985.
9. "Neurological complications of systemic cancer", Guest speaker, Atlantic Neuroscience Meeting, Halifax, Nova Scotia, April 1985.
10. "Monoclonal antibodies: applications to the biology, diagnosis and treatment of brain tumors", Neuro-oncology Course, American Academy of Neurology, Dallas, Texas, April 1985.
11. "Cell density dependent glial filament expression: relationship to differentiation", Biomembranes Group Seminar, University of Western Ontario, London, Ontario, November 1985.
12. "Biology of astrocytoma: lessons learned from chronic myelogenous leukemia - hypothesis", London Neurosciences Association, London, Ontario, March 1986.
13. "Brain metastasis", Neuro-oncology Course, American Academy of Neurology, New Orleans, Louisiana, April 1986.
14. "Biology of astrocytoma: lessons learned from chronic myelocytic leukemia - hypothesis", McGill Cancer Centre Seminar Series, Montreal, Quebec, May 1987.
15. "Malignant glioma: post-surgical changes and steroid effects mimicking treatment response", Montreal Neurological Institute, Montreal, Quebec, May 1987.
16. "Oligodendroglioma: a chemosensitive tumor", Institute of Neurology, Queen's Square, London, UK, November 1988.
17. "Biology and treatment of well-differentiated gliomas", Neuro-oncology Course, American Academy of Neurology, Chicago, Illinois, May 1989.
18. "Supratentorial anaplastic glioma in adults - prognostic importance of extent of resection and prior low grade glioma", Erasmus University, Rotterdam, Netherlands, September 1989.
19. "Supratentorial anaplastic glioma in adults - prognostic importance of extent of resection and prior low grade glioma", University of Leiden, Leiden, Netherlands, September 1989.
20. "Intermediate and low grade gliomas - advances and controversies", Neuro-oncology Course, American Academy of Neurology, Boston, Massachusetts, May 1991.
21. "Chemotherapy for oligodendroglioma", British Columbia Cancer Agency, Vancouver, B.C., May 1991.
22. "Chemotherapy for oligodendroglioma", University of Hamburg, Hamburg, Germany, June 1991.
23. "Chemotherapy for oligodendroglioma", Cleveland Clinic, Cleveland, Ohio, November 1991.

24. "Chemotherapy for oligodendroglioma - progress report", Yale University, New Haven, Connecticut, March 1992.
25. "Is there a role for chemotherapy in the treatment of malignant glioma?", Neuro-pharmacology Course, American Academy of Neurology, San Diego, California, May 1992.
26. "Chemotherapy for oligodendroglioma - progress report", University of Bonn, Bonn, Germany, May 1992.
27. "Chemotherapy for oligodendroglioma - progress report", University of Alabama, Birmingham, Alabama, January 1993.
28. "Chemotherapy for oligodendroglioma - progress report", Massachusetts General Hospital, Boston, Massachusetts, September 1993.
29. "Chemotherapy for oligodendroglioma - progress report", Montreal General Hospital, Montreal, Quebec, October 1993.
30. "Chemotherapy for oligodendroglioma - progress report", Tumors of the Nervous System, Harvard University (CME), Boston, Massachusetts, November 1993.
31. "Chemotherapy for oligodendroglioma - progress report", University of Minnesota, Minneapolis, Minnesota, November 1993.
32. "Chemotherapy for oligodendroglioma - progress report", Mayo Clinic, Rochester, Minnesota, March 1994.
33. "Chemotherapy for oligodendroglioma", American Society of Clinical Oncology, Dallas, Texas, May 1994.
34. "Chemotherapy for oligodendroglioma - progress report", Toronto Hospital, Toronto, Ontario, October 1994.
35. "Chemotherapy for oligodendroglioma - progress report", Cornell University Medical Center/New York Hospital, New York, New York, December 1994.
36. "Chemosensitive gliomas: Which Ones and Why", Memorial Sloan Kettering Cancer Center, New York, New York, December 1994.
37. "Chemotherapy for oligodendroglioma - progress report", Princess Margaret Hospital, Toronto, Ontario, February 1995.
38. "Chemotherapy for oligodendroglioma", Neuro-Oncology Symposium, American Neurological Association, Washington, DC, October 1995.
39. "Chemotherapy for oligodendroglioma - progress report", Tumors of the Nervous System, Harvard University (CME), Boston, MA, November 1995.
40. "Oligodendroglioma and PCV: Serendipity to Science", American Association of Neurological Surgeons, Minneapolis, MN, May 1996.

41. "Chemotherapy for oligodendroglioma - progress report", Dartmouth-Hitchcock Medical Center, Lebanon, NH, September 1996.
42. "Topotecan for malignant glioma", European Organization for Neuro-Oncology, Wurzburg, Germany, October 1996.
43. "Oligodendroglioma: Serendipity to Science", University of Utah, Salt Lake City, Utah, March 1997.
44. "Low and high grade gliomas in adults: management '97" "*Meet the Professor*", American Society of Clinical Oncology, Denver, Colorado, May 1997.
45. "Oligodendroglioma: Serendipity to Science", Loyola University Medical Center, Maywood, Illinois, June 1997.
46. "Chemosensitive Gliomas: Which Ones and Why", Huntsman Cancer Institute, Salt Lake City, Utah, August 1997.
47. "Chemosensitive Gliomas: Which Ones and Why", New York University, New York, NY, November 1997.
48. "Chemosensitive Gliomas: Which Ones and Why", Danish Oncology Society, Copenhagen, Denmark, November 1997.
49. "Oligodendroglioma: Therapeutics Meets Genetics", University of Pennsylvania Cancer Centre - Neuro-Oncology Symposium, Philadelphia, PA, March 1998.
50. "Brain Tumor Treatment - Update '98", American Academy of Neurology, Minneapolis, MN, April 1998.
51. "Oligodendroglioma: Therapeutics Meets Genetics", 9th Canadian Neuro-Oncology Meeting, Niagara-on-the-Lake, Ontario, May 1998.
52. "Oligodendroglioma: Therapeutics Meets Genetics", Henry A. Gamson Memorial Lecture, Evanston Hospital, Evanston, IL, June 1998.
53. "Oligodendroglioma: Therapeutics Meets Genetics", University of Michigan, Ann Arbor, MI, September 1998.
54. "Oligodendroglioma: Therapeutics Meets Genetics", German/Austrian Society of Hematology and Oncology, Frankfurt, Germany, October 1998.
55. "Oligodendroglioma: Therapeutics Meets Genetics", Allentown Neurology Associates, Allentown, PA, November 1998.
56. "Oligodendroglioma: Therapeutics Meets Genetics", Atlantic Clinical Oncology Group Meeting, Cornerbrook, Newfoundland, February 1999.
57. "Oligodendroglioma: Therapeutics Meets Genetics", Robarts Research Institute, London,

Ontario, May 1999.

58. "Oligodendroglioma: Therapeutics Meets Genetics", Ottawa General Hospital, Ottawa, Ontario, May 1999.
59. "Oligodendroglioma: At the Intersection of Treatment and Research", Michael Bell Memorial Lectureship, Adult and Pediatric Brain Tumor Information Day, London, Ontario, October 1999.
60. "The Future of Brain Tumor Therapy", Adult and Pediatric Brain Tumor Information Day, London, Ontario, October 1999.
61. "Oligodendroglioma: Therapeutics Meets Genetics", The Arthur and Sonia Labatt Brain Tumour Lecture, Hospital for Sick Children, Toronto, Ontario, January 2000.
62. "Oligodendroglioma: Therapeutics Meets Genetics", Neuro-Oncology Symposium: Current Concepts 2000, hosted by the Cleveland Clinic Foundation, Naples, Florida, February 2000.
63. "Oligodendroglioma: Therapeutics Meets Genetics", Windsor Regional Cancer Centre, Windsor, Ontario, April 2000.
64. "Oligodendroglioma: Therapeutics Meets Genetics", Oregon Health Sciences University, Portland, Oregon, April 2000.
65. "Oligodendroglioma: Therapeutics Meets Genetics", The Michael S. Voynick Award Lecture, Yale University School of Medicine, New Haven, Connecticut, May 2000.
66. "Glioma Histology 2000: Going, Going, ...!" Ninth Biannual Canadian Neuro-Oncology Meeting, Vancouver, B.C., May 2000.
67. "Oligodendroglioma: Therapeutics Meets Genetics", John Gagliarducci Memorial Lecture, Cleveland Clinic Foundation, Cleveland, Ohio, August 2000.
68. "Oligodendroglioma: At the Intersection of Treatment and Research", Colorado Neurological Institute, Denver, Colorado, September 2000.
69. "Advances in Treatment of Low and High Grade Glioma", the 3rd Khadiwala Memorial Lecture in Neuro-Oncology, Colorado Neurological Institute, September 2000.
70. "Evolving Translational Research - Progress in Neurooncology", American Neurological Association, Boston, Massachusetts, October 2000.
71. "Molecular Genetics and the Management of Glioma", The Vrije Universiteit, Amsterdam, The Netherlands, April 2001.
72. "Chemotherapy for Glioma", The Vrije Universiteit, Amsterdam, The Netherlands, April 2001.
73. "Molecular Determinants of Drug Response in Glial Tumors", Montreal Neurological Institute, McGill University, May 2001.
74. "Molecular Determinants of Drug Response in Glial Tumors", Third International Symposium

- on Neuro-Oncology, Buenos Aires, Argentina, September 2001.
75. "Chemotherapy for Oligodendroglioma - Progress Report", Third International Symposium on Neuro-Oncology, Buenos Aires, Argentina, September 2001.
 76. "The Management of Patients with Low Grade Glioma", Third International Symposium on Neuro-Oncology, Buenos Aires, Argentina, September 2001.
 77. "Oligodendroglioma: At the Intersection of Therapeutics, Genetics and Development". Memorial Sloan Kettering Cancer Center, New York, NY, October 2001.
 78. "Oligodendroglioma: At the Intersection of Therapeutics, Genetics and Development". University of Calgary, Calgary, Alberta, November 2001.
 79. "Cancer Diagnosis and Therapy - Moving Beyond Histology". Grand Rounds. London Regional Cancer Centre, London, ON, January 2002.
 80. "Understanding Brain Tumor - One Oligodendroglioma at a Time". Visiting Professor Lecture. Henry Ford Hospital, Detroit, MI. February 2002.
 81. "Understanding Brain Tumor: One Oligodendroglioma at a Time". The Cleveland Clinic Foundation, Cleveland, OH, April 2002.
 82. "Molecular Profiling and Predicting Therapeutic Response in Glioma". 5th Congress of the European Association for Neuro-Oncology. Florence, Italy, September 2002.
 83. "Managing Glioma in the Molecular Era" Crolla Family Brain Tumor Lecture. Sunnybrook and Women's Health Sciences Centre, Toronto, Ontario, January 2003.
 83. "Managing Glioma in the Molecular Era". Frontiers in Clinical Neuroscience Plenary Lecture. American Academy of Neurology, Honolulu, Hawaii, April 2003.
 84. "Molecular Biology of Oligodendroglioma". Neurobiology Review Course. Canadian Congress of Neurological Sciences, Quebec City, Quebec, June 2003.
 85. "Glioma: Molecular Genetics in the Clinic". Brain Tumor Course. Canadian Congress of Neurological Sciences, Quebec City, Quebec, June 2003.
 86. "Managing Glioma in the Molecular Era". American Society of Therapeutic Radiation Oncology, Salt Lake City, Utah, October 2003.
 87. "Managing Glioma in the Molecular Era". Alberta Cancer Board Annual Research Meeting, Banff, Alberta, November 2003.
 88. "Managing oligodendroglioma and oligoastrocytoma in the molecular era: Advances in the treatment of brain tumor. New York University, New York, NY, May 2004.
 89. "Managing glioma in the Molecular era". Brain Tumor Symposium, The Hague, Netherlands, November, 2004.

90. "Managing glioma in the Molecular era". Brain Tumor Symposium, Huntsman Cancer Institute, Salt Lake City, UT, January 2005.
91. "Managing Glioma in the Molecular Era" Brain Tumor Symposium, Kimmel Cancer Centre, Philadelphia, PA, March 2005.
92. "Managing Glioma in the Molecular Era" Mayo Clinic, Rochester, MN, September 2005.
93. "Managing Glioma in the Molecular Era" The Betty Carr Lefkowitz Lecture, University of Alabama Birmingham, Birmingham, AB, October, 2005.
94. "Managing Glioma in the Molecular Era" Department of Genetics, University of Calgary, Calgary, AB, November, 2005.
95. "Understanding Oligodendroglioma" Clinical Neuroscience Program, Dalhousie University, Halifax, NS, March, 2006.
96. "Advances in the Treatment of Glioblastoma" Nova Scotia Cancer Centre, Dalhousie University Halifax, NS, March 2006.
97. "Perspective on the Treatment of Low and High Grade Glioma" British Columbia Cancer Agency, Vancouver, BC, October 2006.
98. "Perspective on the Treatment of Low and High Grade Glioma" Montreal Neurological Institute, Montreal, QC, October 2006.
99. "Perspective on the Treatment of Low and High Grade Glioma" University of Laval, Quebec City, October 2006.
100. "Oligodendroglioma: At the Intersection of Medicine and Science" Charles B Wilson Lecture, University of California at San Francisco, January 2007.
101. "Oligodendroglioma: At the Intersection of Medicine and Science" University of British Columbia, Vancouver, BC, March 2007.
102. "Oligodendroglioma: At the Intersection of Medicine and Science" Brian D. Silber Lecture Massachusetts General Hospital, Boston, MA, April 2007.
103. "Oligodendroglioma: At the Intersection of Medicine and Science" Northwestern University, School of Medicine, Chicago, Illinois, October 2007.
104. "Managing Glioma in the Molecular Era" Department of Neurology, Evanston Hospital, Evanston, Illinois, October 2007.
105. "Oligodendroglioma: At the Intersection of Medicine and Science" Rocky Mountain Symposium. Kannanaskis, Alberta, March, 2008.

